Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a rheumatoid arthritis drug help heal traumatic brain injuries?

NCT ID NCT06065046

Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether baricitinib, a drug used for arthritis, can help people recover from moderate to severe traumatic brain injuries that involve bleeding in the brain. About 100 adults will receive the drug or a placebo within 24 hours of injury. The main goal is to see if it improves long-term function and reduces inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years older and younger than 80 years old. 2. Definite history of traumatic brain injury. 3. Admission within≤24 hours after the traumatic brain injury. 4. CT scans demonstrate intracerebral hemorrhage/contusions with and without extracerebral hemorrhage (epi- and sub- dural hemorrhage) 5. GCS score of 5 or greater and no more than 12 at time of enrollment. 6. Closed head injury. 7. Admission without infections 8. Signed and dated informed consent by the subject, legally authorized representative, or surrogate obtained. Exclusion Criteria: 1. Time of head injury cannot be reliably assessed. 2. Subjects is considered a candidate for immediate surgical intervention because of severe extracranial injury. 3. Open head injury. 4. Pregnancy or parturition within previous 30 days or active lactation. 5. Use of Janus kinase inhibitors (baricinitib,abroctinib, AG490 and etc.) 6. Pre-traumatic dementia or disability. 7. With severe liver, kidney disease, or malignancy, life expectancy is less than 14 days. 8. Severe pulmonary infection. 9. Severe or acute heart failure. 10. Severe infections within previous 30 days. 11. History of myocardial infarction. 12. Known sensitivity to baricinitib. 13. Severe decreases in neutrophil, lymphocyte and platelet counts, severe decrease in hemoglobin. 14. Severe liver and kidney dysfunction. 15. Currently participating in other interventional clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Traumatic brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Injuries, Traumatic Cerebral Hemorrhage, Traumatic intracerebral hemorrhage traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Traumatic brain injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tandu Hospital, Fourth Military Medical University

    RECRUITING

    Xi'an, Shaanxi, 710038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.